Thromboembolic prophylaxis with low molecular weight heparin in risk pregnancy;Thromboembolieprophylaxe mit niedermolekularem heparin (dalteparin-Na) bei risikoschwangerschaften

Medizinische Klinik

Volumn 97, Issue 4, 2002, Pages 193-203

  Schinzel, Helmut ^a   Bahlmann, Franz ^a   Peetz, Dirk ^a   Savvidis, Savvas ^a   Himmrich, Ludmilla ^a   Klotz, Myriam ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Low molecular weight heparin; Risk pregnancy; Thromboembolic prophylaxis

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; DISEASE PREDISPOSITION; FEMALE; HUMAN; PREGNANCY; PUERPERIUM; RISK FACTOR; THROMBOEMBOLISM; THROMBOGENESIS;

ADOLESCENT; ADULT; ANTITHROMBIN III; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INFANT, NEWBORN; INJECTIONS, SUBCUTANEOUS; PEPTIDE HYDROLASES; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY, HIGH-RISK; RECURRENCE; SELF ADMINISTRATION; THROMBOEMBOLISM;

EID: 0037090509     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-002-1146-8     Document Type: Article

References (57)

1. Low-molecular-weight heparin for thrombophilia in pregnant women
2. Aktuelles management der tiefen venenthrombose
3. Anticoagulant effects of two types of low molekular weight heparin administered subcutaneouslsy
4. Hypercoagulability and thrombosis
5. Antiphospholipid syndrome and thrombosis
6. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters
7. Changes in blood coagulation and fibrinolysis during pregnancy and die menstrual cycle: New methods for detecting the changes
8. Hyperhomocysteinemia as a risk factor for arterial and venous diseases. A review of evidence and relevance
9. Epidemiology of venous thromboembolism in pregnancy and the puerperium
10. Hyperhomocysteinemia a risk factor for arterial and venous thrombotic disease
11. Thrombosis in pregnancy and congenital deficiencies in AT III, protein C or protein S: Study 78 women
12. Thrombosis prophylaxis after treatment during pregnancy
13. Low molecular weight heparin treatment in a pregnant woman with allergy to standard heparins and heparinoid
14. Thrombosis during pregnancy, and surgery in patients with congenital deficiency of antithrombin III, protein C-protein S
15. Prolonged heparin therapy in pregnancy causes bone demineralisation
16. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
17. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis
18. Venöse thromboembolieprophylaxe mit heparin bei risikopatientinnen während der schwangerschaft: Monitorisierung mittels messung der thrombin-antithrombin-III-komplexe
19. Low molecular weight heparin (CY216) does not cross the placenta during the third trimester of pregnancy
20. D-dimer plasma levels during normal pregnancy measured by specific ELISA
21. Use of low molecular weight heparin for prophylaxis and treatment ofthromboembolism in pregnancy
22. Anticoagulants during pregnancy
23. Use of antithrombotic agents during pregnancy
24. Heparin effects on bone density
25. Thromboembolic problems in pregnancy
26. The special case of venous thromboembolism in pregnancy
27. Heparin osteoporosis
28. Maternal and fetal sequelae of anticoagulation during pregnancy
29. Thromboemboliepropllylaxe mit niedermolekularem heparin in der schwangerschaft
30. Lack of anti-Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women
31. Treatment of and prophylaxis of thromboembolic complications during pregnancy and puerperium
32. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis
33. Pregnancy in women with thrombophilla: Incidence of thrombosis and pregnancy outcome
34. Thromboembolische erkrankungen in der geburtshilfe
35. Risk of anticoagulant therapy in pregnant women with artificial heart valves
36. Four heparin preparations. Anti-Xa potentiating effect of heparin after subcutaneous injection
37. Heparin-induced thrombocytopenia, thrombosis and haemorrhage
38. Venous thromboembolic disease in obstetrics and gynaecology: The Scottish experience
39. Risk factors for pregnancy associated venous thromboembolism
40. Use of low molecular weight heparin in pregnancy
41. Thrombosis in patients with the "lupus"-type circulating anticoagulant
42. Thrombotic risk in hereditary anti-thrombin III, protein C or protein S deficiency
43. Prospective study of serum total homocysteine concentration and risk of stroke in middle-agged British men
44. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies
45. Thromboembolic prophylaxis with low molecular weight heparin during pregnancy
46. Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin
47. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
48. Maternal mortality in Massachusetts: Trents and prevention
49. Hemorrhagic disorders associated with circulating inhibitors
50. Hyperhomocysteinemia and deep-vein thrombosis: A case-control study
51. Blood coagulation and fibrinolysis during normal pregnancy
52. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke
53. Warfarin embryopathy
54. Fetal and neonatal outcome of exposure to anticoagulants during pregnancy